Bone Marrow Cancer caused by JAK2 mutations and related treatments

Abstract

JAK2 V617F, one of the protein mutations, will cause uncontrolled blood production. The mutation leads to a lot of blood and bone marrow diseases, for instance, myeloproliferative neoplasms, myelofibrosis, leukemia et al. Most of these diseases are deadly. Uncontrolled blood cell production might result in leukemia, myelofibrosis, and bone marrow cancer even worse. However, The development of treatments has not been perfected, so mutations in the JAK2 protein still put patients at risk. This article analyzes the mutation principle of JAK2. Many diseases are caused by mutations. At the same time, experiments have confirmed that JAK2 mutations cross-species and do not only occur in humans. In addition, this article explains the treatment options for diseases caused by JAK2 mutations, such as eBM Treatment and Target Therapy. The research provides the stage that concluded the mutant mechanism and the several treatments for the disease caused by the mutation. Although some of the treatments and therapies are not consummated, the future research orientation could be more focused on the clinical study of target therapies like Parental Proteasome Inhibitors.